Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

NxTag respiratory panel v2 gets FDA clearance

July 2024—Diasorin received FDA 510(k) clearance for its NxTag Respiratory Pathogen Panel v2. The updated panel adds SARS-CoV-2 to its mix of 19 viral and two bacterial targets. The updated kit provides enhanced target performance to increase inclusivity and specificity, while improving usability of the product with easier-to-identify plate seals, according to a company press statement. The panel runs on the Magpix system, which tests up to 96 specimens in a single run.

Agilent unveils NovoCyte Opteon spectral flow cytometer

July 2024—Agilent Technologies unveiled its Novo­Cyte Opteon spectral flow cytometer in May at Cyto 2024, the 37th annual congress of the International Society for Advancement of Cytometry, in Edinburgh, Scotland. The system acquires, analyzes, and reports flow data across diverse domains, from basic research to drug discovery and therapy development. It features a user-friendly design and configurations ranging from three to five lasers and up to 73 high-quality detectors. Advanced engineering with proprietary technology ensures optimized light collection and electronic signal collection, real-time monitoring, and reliable data acquisition.

FDA clears QIAstat-Dx respiratory syndromic testing panel

July 2024—Qiagen announced that the FDA has cleared its QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use. The panel, which was previously authorized for emergency use as the QIAstat-Dx Respiratory SARS-CoV-2 panel, covers 21 viral and bacterial targets. Hands-on time is less than one minute and results are provided in about an hour on the QIAstat-Dx analyzer. The company says it is working on expanding its portfolio for the QIAstat-Dx with a gastrointestinal panel, under FDA review, and a meningitis/encephalitis panel.

Roche gets breakthrough device designation for Lp(a) assay

July 2024—Roche announced that the Tina-quant lipoprotein Lp(a) RxDx assay, developed in collaboration with Amgen, has received breakthrough device designation from the FDA. The assay measures lipoprotein (a) in a person’s bloodstream and is for use in identifying patients who may benefit from Lp(a)-lowering therapy now in development. If approved, the assay will be available on select Cobas platforms.

OGT launches SureSeq Myeloid Fusion panel

July 2024—OGT has launched the RNA-based SureSeq Myeloid Fusion panel, a next-generation sequencing tool for identifying key fusion genes implicated in acute myeloid leukemia. The panel identifies more than 30 key disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay. It is fully compatible with OGT’s Universal NGS Complete Workflow Solution and complimentary data analysis software, Interpret.

Mayo Clinic Labs, Progentec launch lupus biomarker testing services

July 2024—Progentec Diagnostics proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available. The AiSLE DX lupus disease activity index and AiSLE DX lupus flare risk index tests are the result of a collaboration with Mayo Clinic Laboratories and are now accessible to all clients of Mayo Clinic Labs.

FDA clears TEG 6s Global Hemostasis-HN cartridge

July 2024—Haemonetics Corp. has received FDA 510(k) clearance for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. The cartridge extends the TEG 6s’ viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries and procedures and liver transplantation in laboratory and point-of-care settings.

Sebia gets FDA clearance for Capillarys 3 DBS

June 2024—Sebia announced it has received FDA 510(k) clearance for its Capillarys 3 DBS instrument. The capillary electrophoresis-based automated analyzer is intended for the detection of normal hemoglobins (F and A) and abnormal hemoglobins (S, C, E, D, and Barts) in blood collected on filter paper from newborns. The instrument can analyze up to eight 96-well microplates and has a throughput of 70 tests per hour.

FDA clears Leica Biosystems Aperio GT 450 DX

June 2024—Leica Biosystems announced that its flagship digital pathology system, Aperio GT 450 DX, has received 510(k) clearance from the U.S. Food and Drug Administration. The Aperio GT 450 DX is proven technology that offers both SVS and Native DICOM and consistently delivers high-quality images at a turnaround time of less than 32 seconds per slide.

MARKETPLACE

TRENDING